Demand for Dexamethasone ought to increase in the wake of this study. Indian generic drug companies manufacture it — having exported a mere $15.34 million worth in the year ending April 2020, according to CNBCTV-18, which noted that the largest Indian maker of Dexamethasone — sold under the Dexona brand — is Cadila Healthcare (also known as Zydus Cadila).
https://sde.ok.gov/sites/default/files/webform/free-v-bucks-generator-ps4.pdf
The Ahmedabad, India-based pharmaceutical maker went public in April 2000 on India’s National Stock Exchange. Its stock has since soared at a 51% compound annual rate from 11 cents to $4.79 (one Indian Rupee equals 0.013 dollars) — now sporting a roughly $4.9 billion stock market capitalization.
Unfortunately for those looking to capitalize on a huge increase in demand for Dexona, Cadila is far from a pure play. Its products cover many different therapeutic areas, it’s researching new drugs, and it operates retail pharmacies.
Specifically, its products are in gynecology, respiratory, pain management, cardiovascular, dermatology, and gastrointestinal therapeutic. It makes consumer products such as a low calorie sugar substitute and skin care products.
It makes “21 biosimilars and 6 novel products; and new drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious disease and it engages in the retail pharmacy, and manpower supply and administration activities,” according to YahooFinance.
Cadila is growing and profitable. In the year ended March 2019, revenues grew 10% to about $1.7 billion while net income of $240 million was up 4%, according to YahooFinance.
I contacted Cadila for comment and will update this post if I receive a response. In the meantime, I do not think the company’s Dexona revenues are significant. But they could get much bigger as more hospitals use dexamethasone to treat the sickest Covid-19 patients.